جامعة المعرفة
المصدر المعتمد للمعلومات البحثية والمخرجات هو قاعدة بيانات سكوبس (Elsevier Scopus) مع تدقيق بيانات الباحثين من عمادة البحث العلمي.

Research outputs

المخرجات البحثية

مقالات ومراجعات وأوراق مؤتمرات وفصول كتب، مفهرسة برقم DOI ومربوطة بباحثي الجامعة.

17 مُخرَج نتائج البحث عن «Heart failure»

مراجعةوصول مغلق2026

Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure in Children and Adolescents: A Single-Arm and Pairwise Systematic Review and Meta-Analysis with GRADE Assessment of the Evidence

Cardiology in Review

Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a cornerstone of adult heart failure (HF) therapy and are increasingly prescribed off-label to children, yet pediatric outcomes have never been pooled. We searched PubMed/MEDLINE, Embase, Scopus, and Web of Science to 14 August 2026 for studies of any SGLT2 inhibitor in children or adolescents with HF and performed a single-arm meta-analysis of all exposed patients and a pairwise meta-analysis of the comparative studies with random-effects models. Nine studies contributed 599 exposed patients and 97 controls. Pooled rates were 3.8% (95% confidence interval [CI] 1.6-8.4) for mortality, 8.5% (6.2-11.5) for transplantation, 11.2% (8.2-15.1) for worsening HF, 0.2% (0.03-1.6) for ketoacidosis, 4.5% (1.2-14.9) for acute kidney injury, 3.7% (1.1-11.7) for urinary tract infection, and 4.1% (1.4-11.2) for discontinuation because of an adverse event. After initiation, left ventricular ejection fraction rose by 7.7 percentage points (3.6-11.8) and natriuretic peptide fell by 0.42 standard deviations (0.34-0.49). In the comparative synthesis (63 exposed, 97 unexposed), risk ratios were 0.80 (0.11-6.07) for mortality and 0.21 (0.03-1.68) for worsening HF; ejection fraction improved 3.34 percentage points more with SGLT2 inhibitors (0.22-6.46) whereas natriuretic peptide did not differ (standardized mean difference -0.09, -0.50 to 0.33).

SGLT2 inhibitorsheart failurepediatric heart failurechildren and adolescents
مراجعةوصول مفتوح2026

The Impact of Preexisting Cardiac Implantable Electronic Devices on the Safety of Transcatheter Tricuspid Valve Interventions: A Systematic Review and Meta-Analysis

Journal of Cardiovascular Development and Disease · مجلد 13 (10) · 478-478

Background: Tricuspid regurgitation (TR) increases mortality but remains undertreated due to high surgical risks. Transcatheter tricuspid valve interventions (TTVI) offer safer alternatives, improving functional status and quality of life. However, many candidates for TTVI have trans-tricuspid CIED leads that may interfere with procedural imaging and device deployment and may be exposed to dislodgement, entrapment, or jailing. Evidence regarding both clinical outcomes and postprocedural CIED function in this population remains limited. Existing trial evidence for this population is scarce, requiring further safety analysis. To our knowledge, this is the first meta-analysis to address the comparative risk of complications and residual TR in patients with vs. without CIEDs. Methods: We searched for relevant articles up to March 2026 from PubMed, Scopus, Cochrane Library, and Web of Science. Two independent reviewers extracted data from the selected studies, including baseline information, outcomes, comorbidities, hospitalization metrics, TR severity, and complications. All data analyses were performed using R version 4.4.1. Results: Ten studies comprising 5415 patients were included. Nine comparative studies contributed to the quantitative synthesis, whereas one single-arm study contributed only to the narrative synthesis of CIED-specific mechanical and electrical outcomes. In patients undergoing TTVI, across two studies, patients with CIEDs had a nominally lower risk of single-leaflet device attachment (RR 0.34, 95% CI 0.12–0.94; nominal p = 0.037); however, this exploratory finding should be considered hypothesis-generating. However, no statistically significant differences were observed between groups for cardiovascular death (RR 1.30, p = 0.815), device embolization (RR 1.62, p = 0.666), device malposition (RR 1.10, p = 0.909), stroke (RR 0.52, p = 0.335), hospitalization for heart failure (RR 1.02, p = 0.931), in-hospital mortality (RR 1.02, p = 0.959), major adverse events (RR 0.74, p = 0.635), major bleeding (RR 0.70, p = 0.187), or residual tricuspid regurgitation of mild (RR 0.98, p = 0.686) or moderate severity (RR 1.01, p = 0.646). CIED-specific outcomes were reported heterogeneously. Lead function was generally preserved after T-TEER in carefully selected patients, whereas studies of TTVR with jailed leads reported lead failure or malfunction ranging from 5.8% to 21% in individual cohorts. Conclusions: Among the comparative outcomes available for quantitative pooling, no statistically significant differences were detected between patients with and without CIEDs for most procedural and postprocedural outcomes. However, CIED-specific risks differed according to the intervention. Lead function was generally preserved after T-TEER in carefully selected patients, whereas lead jailing during TTVR was associated with clinically relevant lead malfunction in some cohorts. Therefore, the absence of significant differences in pooled clinical outcomes should not be interpreted as evidence that TTVI does not affect CIED function.

transcatheter tricuspid valve interventiontricuspid regurgitationcardiac implantable electronic devicesdevice embolization
ملخص مؤتمروصول مفتوح2026

Diagnostic Accuracy of Modalities For Acute Heart Failure In Emergency Settings. A Systematic Review and Diagnostic Accuracy Meta-Analysis

Saudi Journal of Emergency Medicine · مجلد 7 (1S) · 91-91

Background: Acute heart failure diagnosis in emergency departments remains challenging despite multiple available diagnostic modalities. Current emergency evaluations rely variably on clinical assessment, biomarkers, and ultrasound techniques; however, their comparative diagnostic accuracy remains inadequately compared in previous studies. This systematic review and meta-analysis aim to evaluate the diagnostic accuracy of four categories of diagnostic approaches: Clinical Assessment, Biomarker Assessment, Basic Ultrasound Assessment, and Advanced Ultrasound Assessment for diagnosing acute heart failure in emergency settings. Methods: We conducted a literature review across PubMed/MEDLINE, Scopus, Google Scholar, Cochrane Library, Google Scholar, and Web of Science up to December 2024. Studies investigating the diagnostic modalities for acute heart failure in emergency settings with sufficient data to construct 2×2 contingency tables were included. Two independent reviewers performed screening, data extraction, and quality assessment using QUADAS-2. Diagnostic accuracy was synthesized using a bivariate random-effects model. Summary receiver operating characteristic (SROC) curves, pooled sensitivity, specificity, and area under the curve (AUC) were calculated with 95% confidence intervals (CI). Heterogeneity was assessed using I² statistics and publication bias with Deeks' funnel plot. Results: Thirty-three studies including a total of 17 participants to 1,586 participants met the inclusion criteria. Clinical Assessment demonstrated moderate diagnostic performance (AUC=0.591) with limited sensitivity (0.500, 95% CI: 0.484-0.515) but high specificity (0.858, 95% CI: 0.830-0.886). Biomarker Assessment showed excellent performance (AUC=0.906) with high sensitivity (0.874, 95% CI: 0.872-0.875) and good specificity (0.781, 95% CI: 0.778-0.783). Basic Ultrasound Assessment had moderate performance (AUC=0.750) with low sensitivity (0.349, 95% CI: 0.303-0.395) but high specificity (0.889, 95% CI: 0.874-0.904). Advanced Ultrasound Assessment demonstrated excellent performance (AUC=0.892) with good sensitivity (0.713, 95% CI: 0.705-0.720) and very high specificity (0.903, 95% CI: 0.900-0.905). All modalities showed remarkably consistent performance across studies (I²=0%). Conclusion: Biomarker Assessment provides the highest overall diagnostic accuracy for acute heart failure in emergency settings, while Advanced Ultrasound Assessment offers the optimal balance between sensitivity and specificity when equipment and expertise are available. Clinical Assessment alone has limitations for detecting acute heart failure but remains useful for exclusion. Our findings highly recommend adapting a multimodal diagnostic approach integrating biomarkers and advanced ultrasound techniques whenever possible for optimal diagnostic accuracy in emergency settings.

acute heart failureemergency diagnosisdiagnostic accuracyclinical evaluation
مقالوصول مفتوح2026

Cardiac safety of sofosbuvir-based direct-acting antivirals in hepatitis C patients with pre-existing heart disease

Clinics · مجلد 81 · 100908-100908

BACKGROUND: Direct-Acting Antivirals (DAAs) are effective in 95% of patients, but concerns about potential cardiotoxicity and decreased Warfarin Sensitivity (WS) need further investigation. The study aimed to evaluate the safety and effectiveness of sofosbuvir-based therapy in patients with significant heart diseases, considering potential drug interactions and their impact on cardiac function. METHODS: The study involved 100 patients with HCV genotype 4, including 40 with ischemic heart disease, 20 with prosthetic valve replacement, 20 with NYHA class I‒II heart failure, and 20 with systemic hypertension. All received sofosbuvir-based antiviral therapy and underwent routine laboratory tests, N-Terminal B-type Natriuretic Peptide (NT-Pro BNP), abdominal ultrasound, and echocardiography at baseline and three months post-treatment. RESULTS: Ninety-six patients achieved SVR, resulting in improved cardiac ejection fraction (EF) from 53.2 ± 8.8% to 56.2 ± 6.9% (p = 0.000) and reduced left atrial volume (LAV) from 43.2 ± 4.2 to 41.7 ± 3.9 mm (p = 0.008). Liver stiffness also improved (p = 0.013), and no disabling symptoms were reported. MAPSE increased from 8.4 ± 2.4 mm to 9.5 ± 2.5 mm, and interventricular septum thickness (IVT) decreased from 12.5 ± 1.8 mm to 10.9 ± 1.3 mm (p = 0.001 and P = 0.000, respectively). The warfarin dose needed to be increased to optimize INR after SVR, but this adjustment did not affect WS (p = 0.16). CONCLUSION: Sofosbuvir-based antiviral therapy was well tolerated and demonstrated a reassuring cardiac safety profile in HCV patients with pre-existing heart disease, with no major arrhythmias or adverse cardiac events observed during or after therapy.

sofosbuvirdirect-acting antiviralshepatitis CHCV genotype 4
مراجعةوصول مغلق20251استشهاد· Semantic Scholar

Angiotensin-neprilysin inhibition in acute decompensated heart failure: a systematic review and meta-analysis of randomized controlled trials

European Heart Journal · مجلد 46 (Supplement_1)

Abstract Purpose Angiotensin receptor-neprilysin inhibitors (ARNI) are well-established for chronic heart failure (HF) with reduced ejection fraction. However, their efficacy and safety when initiated in acute decompensation (ADHF) remain less well characterized. This meta-analysis evaluates the efficacy and safety of ARNI compared to angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) for ADHF. Methods A meta-analysis of randomized controlled trials (RCTs) retrieved from PubMed, Scopus, WOS, Embase, and CENTRAL till November 2024. Risk ratios (RR) were applied for dichotomous outcomes and standardized mean differences (SMD) for continuous outcomes, both with 95% confidence intervals (CI). Results Three RCTs with 1,741 patients were included. Use of ARNI after stabilization of ADHF resulted in a significant reduction of HF rehospitalization/all-cause mortality (RR: 0.71; 95% CI: 0.57 to 0.88; p < 0.01), HF rehospitalization (RR: 0.73; 95% CI: 0.57 to 0.93; p = 0.01), worsening renal function (RR: 0.80; 95% CI: 0.64 to 1.00; p = 0.048), and NT-proBNP at 4 weeks (SMD: -0.24; 95% CI: -0.34 to -0.14; p < 0.0001) or 8 weeks (SMD: -0.21; 95% CI: -0.31 to -0.10; p = 0.0001). However, ARNI was associated with a higher risk of symptomatic hypotension (RR: 1.33; 95% CI: 1.04 to 1.71; p = 0.024). Conclusion Pooled data demonstrate that the initiation of ARNI post-ADHF can be effective compared with ACEIs/ARBs for both cardiovascular and renal benefits at the expense of increased risk for symptomatic hypotension.

angiotensin receptor-neprilysin inhibitorsacute decompensated heart failureACE inhibitorsangiotensin receptor blockers
مقالوصول مفتوح2025

HearteXplain: explainable prediction of acute heart failure and identification of hematologic biomarkers using EBMs and Morris sensitivity analysis

Scientific Reports · مجلد 15 (1) · 39971-39971

Hematological biomarkers have emerged as powerful tools in diagnosing Acute Heart Failure (AHF). This study introduces a novel diagnostic framework that integrates Explainable Artificial Intelligence (XAI) with Morris Sensitivity Analysis (MSA) to enhance both the interpretability and performance of machine learning models in AHF detection. A dataset consisting of 425 AHF patients and 430 controls was analyzed using eight machine learning models, including XGBoost, Histogram-based Gradient Boosting (histGB), Explainable Boosting Machine (EBM), and Random Forest. Model performance was evaluated through metrics such as AUC, accuracy, precision, recall, and Brier score. Hyperparameters were optimized via Bayesian optimization. Feature importance was assessed using MSA to identify variables with the highest predictive influence. The histGB model achieved the highest performance with an AUC of 87.93%. Both MSA and EBM consistently identified PDW, RDW-CV, NEU, NEU/LY ratio, age, and WBC as top predictive features across multiple models. These hematological markers demonstrated strong potential for early diagnosis and risk stratification in AHF patients. This study presents a clinically relevant, interpretable, and cost-effective diagnostic strategy that combines XAI with MSA for AHF prediction. The framework enhances clinical trust and provides a pathway toward personalized treatment by identifying accessible hematological biomarkers. The integration of explainability into AI models improves their transparency and applicability in real-world clinical settings.

acute heart failurehematological biomarkersexplainable AIexplainable boosting machine
مراجعةمفتوح (مستودع)2025

Angiotensin-neprilysin inhibition in acute decompensated heart failure: a meta-analysis of randomized controlled trials

Future Cardiology · مجلد 22 (1) · 43-55

Background Angiotensin receptor – neprilysin inhibitors (ARNI) are well-established for chronic heart failure (HF) with reduced ejection fraction. However, their efficacy and safety after stabilization of acute decompensation (ADHF) remain unclear. This meta-analysis evaluates ARNI versus angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) post-ADHF.Methods Meta-analysis of randomized controlled trials (RCTs) from PubMed, Scopus, WOS, Embase, and CENTRAL up to November 2024. Risk ratios (RR) and standardized mean differences (SMD) with 95% confidence intervals (CI) were used.Results Three RCTs (1,741 patients) were included. ARNI use after ADHF stabilization significantly reduced HF rehospitalization/all-cause mortality (RR: 0.71; 95% CI: 0.57–0.88; p < 0.01), HF rehospitalization (RR: 0.73; 95% CI: 0.57–0.93; p = 0.01), worsening renal function (RR: 0.80; 95% CI: 0.64–1.00; p = 0.048), and NT-proBNP at 4 weeks (SMD: −0.24; 95% CI: −0.34 to −0.14; p < 0.0001) and 8 weeks (SMD: −0.21; 95% CI: −0.31 to −0.10; p = 0.0001). However, ARNI increased symptomatic hypotension risk (RR: 1.33; 95% CI: 1.04–1.71; p = 0.024).Conclusion initiation of ARNI after ADHF stabilization is more effective than ACEIs/ARBs for cardiovascular and renal outcomes, albeit with higher symptomatic hypotension risk.Protocol registration PROSPERO: CRD42024618027.

angiotensin receptor-neprilysin inhibitorsacute decompensated heart failureACE inhibitorsangiotensin receptor blockers
مقالوصول مفتوح2023

Better survival in morbidly obese patients with atrial fibrillation treated with non-vitamin K-dependent oral anticoagulants

Journal of the Saudi Heart Association · مجلد 35 (1) · 7-15

Background: The efficacy and safety of non-vitamin K-dependent anticoagulants (NOAC) are not well investigated in the obese population, and fixed dosing could lead to under-anticoagulation. Our objective was to evaluate the effect of obesity on anticoagulation outcomes and survival in non-valvular atrial fibrillation (AF) patients. Methods: We enrolled 755 patients who required anticoagulation for AF from 2015 to 2016. We grouped the patients into four groups. Group 1 (n = 297) included patients with BMI< 40 kg/m2 treated with NOACs, Group 2 (n = 358) included patients on warfarin with BMI< 40 kg/m2, Group 3 (n = 57) had patients on NOACs with BMI≥ 40 kg/m2 and Group 4 (n = 43) included patients on warfarin and BMI≥ 40 kg/m2. Study outcomes were the composite endpoint of stroke, bleeding, and survival. Results: Competing risk regression showed that stroke and bleeding were not affected by obesity or treatment (SHR: 1.09 (95% CI: 0.79-1.51); P = 0.62). Older age was the predictor of stroke/bleeding (HR:1.03 (95% CI:1.01-1.06); P = 0.02). Predictors of mortality were heart failure (HR:2.23 (95% CI:1.25-3.97); P = 0.007), lower creatinine clearance (HR: 0.98 (95% CI:0.97-0.98): P < 0.001), non-obese patients on warfarin (HR:3.51 (95%CI:1.6-7.7): P = 0.002) and obese patients on warfarin (HR: 6.7 (95% CI:2.51-17.92); P < 0.001). Conclusion: NOACs could have a similar risk profile to warfarin in obese and non-obese patients with non-valvular AF but could have better survival. Larger randomized trials are recommended.

morbid obesitynon-valvular atrial fibrillationwarfarinsurvival
مقالوصول مفتوح2022

An overview of brady dysrhythmias in the emergency department

International Journal of Community Medicine and Public Health · مجلد 10 (1) · 418-418

Bradyarrhythmias, which include physiological and pathological disorders such as sinus node dysfunction and atrioventricular conduction disturbances are frequent clinical findings in the emergency department. Although some benign bradyarrhythmias do not need treatment, acute unstable bradycardia can lead to cardiac arrest. A thorough history and physical examination should cover potential causes of sinoatrial node dysfunction or atrioventricular block in patients with confirmed or suspected bradycardia. Based on the severity of the symptoms, the underlying causes, the presence of possibly reversible causes, the presence of negative indications, and the danger of asystole progression, bradyarrhythmias are managed. Bradyarrhythmias that are unstable or symptomatic are treated with medication and/or pacing. Bradycardia is described as an adult heart rate of less than 60 beats per minute. Syncope, presyncope, momentary light-headedness or dizziness, exhaustion, dyspnea with exertion, heart failure symptoms, or disorientation brought on by cerebral hypoperfusion are typical signs of bradycardia. Atropine plays a significant role in the management of bradyarrhythmias because it counteracts the impact of the parasympathetic vagus nerve system, which can cause an increase in heart rate. Atropine administration is indicated in cases with vagus-mediated asystole, obstructions in the atrioventricular node, and sinus bradycardia. Installation of temporary pacemaker, permanent pacemaker is also among the effective management strategies of the bradyarrythmias. Diagnosis and management of bradyarrythmias in emergency department is of utmost importance since it can prevent morbidity and mortality. The purpose of this research is to review the available information about an overview of bradydysrhythmias in the emergency department.

bradycardiasick sinus syndromeatrioventricular blockcardiac arrest
مقالمفتوح (مستودع)2022

Impact of left ventricular ejection fraction on hospital and long term outcomes after coronary artery bypass graft surgery

European Heart Journal · مجلد 43 (Supplement_2)

Abstract Background Coronary artery bypass surgery is recommended for patients with extensive coronary artery disease and severely impaired left ventricular ejection fraction (LVEF). Short term clinical outcomes improved due to advanced surgical techniques and perioperative management. Objective To study the impact of pre-operative left ventricular ejection fraction (LV EF) on clinical outcomes during postoperative hospitalization and for 5 years follow up. Methods The study was a retrospective analysis of patients underwent CABG at our tertiary care hospital between January 2016 and August 2020.The primary outcome was mortality and the secondary outcomes included acute cerebrovascular stroke, length of hospitalization, subsequent revascularization, and heart failure. Results The study included 410 patients with a median age of 60 (55–68) years, a hospital mortality of 2.7%, postoperative stroke of 7.6%, acute kidney injury (AKI) of 25.6% and new need dialysis of 5.9%. The patients were divided into 4 groups: 75 (18.3%) patients had LV EF less than 35%, 88 (21.5%) had LV EF 35–45%, 106 (25.9%) had LV EF 45–55% and 141 (34.4%) had LV EF more than 55% with significant differences in frequencies of chronic kidney disease (29.3% vs. 40.9% vs. 23.6% vs. 24.1%, p=0.026), prior cerebral stroke (9.3% vs. 11.4% vs. 8.5% vs. 1.4%, p=0.015), Peripheral vascular disease (8% vs. 18.2% vs. 4.7% vs. 12.1%, p=0.019) respectively. The hospital mortality occurred in (6.7% vs. 0% vs. 0.9% vs. 3.5%, p=0.03), acute cerebrovascular stroke occurred in (14.7% vs. 6.8% vs. 3.8% vs. 7.1%, p=0.031), AKI occurred in (36% vs. 43.2% vs. 17.9% vs. 14.9%, p<0.001), new dialysis was used in (12% vs. 5.7% vs. 1.9% vs. 5.7%, p=0.04), ICU stay was [5 (3–7) vs. 4 (3–11) vs. 4 (3–5) vs. 3 (2–5), p<0.001], post ICU stay was [6 (3–10) vs. 5 (4–8) vs. 4 (3–6) vs. 4 (3–6), p=0.009] in patients with LV EF <35%, LV EF 35–45%, LV EF 45–55% and LV EF >55% respectively. Mortality during follow up occurred in (20% vs. 4.5% vs. 2.8% vs.4.3%, p<0.001), stroke occurred in (8% vs. 4.5% vs.0.9 5% vs. 2.8%, p=0.031), revascularization was done in (2.7% vs. 23.9% vs. 18.9% vs. 12.8%, p=0.009) and readmission with heart failure occurred in (52% vs. 34.1% vs. 10.4% vs. 4.3%, p<0.001) in patients with LV EF <35%, LV EF 35–45%, LV EF 45–55% and LV EF >55% respectively. Conclusion Reduced LV EF was associated with increased hospital mortality, frequent morbidities, and prolonged hospitalization after CABG with higher composite rate of death, stroke, heart failure at 5 years compared with normal or mildly reduced LV EF. Funding Acknowledgement Type of funding sources: None.

left ventricular ejection fractioncoronary artery bypass graftingpreoperative cardiac functionpostoperative mortality
مقالوصول مفتوح2022

Classification, pathophysiology and principle of therapy of shock

International Journal of Community Medicine and Public Health · مجلد 9 (9) · 3613-3613

Shock is a clinical syndrome that results from lack of oxygen utilization or supply to vital organs resulting in hypoxia. Shock is associated with significant morbidity and mortality as if not treated timely can lead to multiple organ failure and death. The mortality rate of shock ranges from 20% to 50%. Shock has several pathophysiologies including intracardiac etiologies such as myocardial infarction, myopathy, or severe arrhythmia which produce altered maturation and cause heart failure while loss of internal or external fluid due to trauma or bleeding often results in hypovolemia. Also, obstruction by extracardiac causes and activation of inflammatory cascade can induce shock. The purpose of this research is to review the available information about the classification, pathophysiology and principle of therapy of shock. The major classification of shock includes cardiogenic, hypovolemic, obstructive and distributive shock. Distributive shock is further divided into three subclasses of septic, anaphylactic and neurogenic shock. Haemorrhagic shock is also the sub-type of hypovolemic shock. Each class of shock requires a specific treatment and timely management to prevent any further complications. Constant examination, resuscitation and re-evaluation are important in therapy of shock. To treat hypotension and to increase cardiac output, vasopressor drugs and inotropic adrenergic drugs continue to be the most widely used therapies. Endogenous catecholamines such as epinephrine, norepinephrine, and dopamine among other vasopressors have been shown to be effective in treating various types of shocks that are controlled as part of treatment for shock. Early diagnosis and prompt treatment can help in prevention of complications of shock also enhancing the recovery of patients.

shockshock classificationcardiogenic shockhypovolemic shock
مقالوصول مفتوح2022

Canagliflozin Reduces the Contractile Response of Isolated Heart of Normal Adult Rats

International Journal of Morphology · مجلد 40 (5) · 1300-1307

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) represent a unique class of glucose-declining renal-targeted drugs.The SGLT2i Canagliflozin (CANA) is an anti-hyperglycemic drug that reduces various cardiovascular and renal outcomes in patients with type 2 diabetes mellitus.This study aimed to explore the potential effects of CANA on the isolated healthy adult rat hearts to show if CANA has positive inotropic or cardiac depressant effects via analyzing the amplitude and frequency of cardiac contractions.In isolated normal adult rat hearts, the effects of CANA on cardiac contractility were examined.In a dose-response curve, CANA led to a significant cardiac depressant effect in a dose-dependent manner.This cardiac depressant effect of CANA (10 -6 M) was not prevented by atropine.However, this cardiac depressant effect was partially antagonized by both Isoproterenol (10 -5 M) and Calcium chloride (10 -6 M), suggesting beta-adrenoceptor and calcium channel blocking actions.In addition, the cardiac depressant effect of CANA (10 -6 M) was mitigated in part by Nitric oxide synthase inhibitor, L-NAME, suggesting that its action probably depends to some extent on the accumulation of nitric oxide, which decreases the rise of intracellular Calcium.Data from this study demonstrate that CANA has a significant cardiac relaxant effect in isolated hearts of healthy adult rats by different possible mechanisms.This inhibitory effect on cardiac contractility may help improve the diastolic ventricular filling providing a therapeutic potential to help the other cardioprotective mechanisms of CANA in the prevention and treatment of heart failure.

canagliflozinSGLT2 inhibitorscardiac contractilityisolated heart
مراجعةوصول مفتوح202145استشهاد· Semantic Scholar

Anticancer Drug-Induced Cardiotoxicity: Insights and Pharmacogenetics

Pharmaceuticals · مجلد 14 (10) · 970-970

The advancement in therapy has provided a dramatic improvement in the rate of recovery among cancer patients. However, this improved survival is also associated with enhanced risks for cardiovascular manifestations, including hypertension, arrhythmias, and heart failure. The cardiotoxicity induced by chemotherapy is a life-threatening consequence that restricts the use of several chemotherapy drugs in clinical practice. This article addresses the prevalence of cardiotoxicity mediated by commonly used chemotherapeutic and immunotherapeutic agents. The role of susceptible genes and radiation therapy in the occurrence of cardiotoxicity is also reviewed. This review also emphasizes the protective role of antioxidants and future perspectives in anticancer drug-induced cardiotoxicities.

chemotherapy-induced cardiotoxicitypharmacogeneticsimmunotherapy cardiotoxicityhypertension